Novo Nordisk's Wegovy pill shows three times more prescriptions than rival Zepbound at a similar launch stage, suggesting strong market lead. However, this data excludes significant cash-pay channels where many weight-loss drug users pay out-of-pocket, providing an incomplete market view. Additionally, the lowest-dose Wegovy formulation is declining, hinting at price sensitivity or shifts to higher-priced options. Competitor Lilly's Foundayo is gaining prescriptions but pharmacy data varies, making early conclusions uncertain. Investors should note that headline prescription numbers may mislead without considering full market dynamics and distribution channels.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
